Advertisement

Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial)

Published:December 17, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.12.008
      Infarct size after ST-segment elevation myocardial infarction (STEMI) is associated with long-term clinical outcomes. However, there is insufficient information correlating creatine kinase-MB (CK-MB) or troponin levels to infarct size and infarct location in first-time occurrence of STEMI. We, therefore, assessed the utility of CK-MB measurements after primary percutaneous coronary intervention of a first anterior STEMI using bivalirudin anticoagulation in patients who were randomized to intralesion abciximab versus no abciximab and to manual thrombus aspiration versus no aspiration. Infarct size (as a percentage of total left ventricular [LV] mass) and LV ejection fraction (LVEF) were evaluated by cardiac magnetic resonance imaging at 30 days and correlated to peak CK-MB. Peak CK-MB (median 240 IU/L; interquartile range 126 to 414) was significantly associated with infarct size and with LVEF (r = 0.67, p <0.001; r = −0.56, p <0.001, respectively). A large infarct size (greater than or equal the median, defined as 17% of total LV mass) and LVEF ≤40% were more common in the highest peak CK-MB tertile group than in the other tertiles (87.6% vs 49.5% vs 9.1%, p <0.001; 43.2% vs 14.0% vs 4.6%, p <0.001, respectively). Peak CK-MB of at least 300 IU/L predicted with moderate accuracy both a large infarct size (area under the curve 0.88) and an LVEF ≤40% (area under the curve 0.78). Furthermore, CK-MB was an independent predictor of 1-year major adverse cardiac events (hazard ratio 1.42 per each additional 100 IU/L [1.20 to 1.67], p <0.001). In conclusion, CK-MB measurement is useful in estimating infarct size and LVEF and in predicting 1-year clinical outcomes after primary percutaneous coronary intervention for first anterior STEMI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burns R.J.
        • Gibbons R.J.
        • Yi Q.
        • Roberts R.S.
        • Miller T.D.
        • Schaer G.L.
        • Anderson J.L.
        • Yusuf S.
        The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.
        J Am Coll Cardiol. 2002; 39: 30-36
        • Gibbons R.J.
        • Valeti U.S.
        • Araoz P.A.
        • Jaffe A.S.
        The quantification of infarct size.
        J Am Coll Cardiol. 2004; 44: 1533-1542
        • Chin C.T.
        • Wang T.Y.
        • Li S.
        • Wiviott S.D.
        • deLemos J.A.
        • Kontos M.C.
        • Peterson E.D.
        • Roe M.T.
        Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines.
        Clin Cardiol. 2012; 35: 424-429
        • Pennell D.J.
        Cardiovascular magnetic resonance.
        Circulation. 2010; 121: 692-705
        • Mahrholdt H.
        • Wagner A.
        • Holly T.A.
        • Elliott M.D.
        • Bonow R.O.
        • Kim R.J.
        • Judd R.M.
        Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging.
        Circulation. 2002; 106: 2322-2327
        • Kim R.J.
        • Albert T.S.
        • Wible J.H.
        • Elliott M.D.
        • Allen J.C.
        • Lee J.C.
        • Parker M.
        • Napoli A.
        • Judd R.M.
        Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial.
        Circulation. 2008; 117: 629-637
        • Hedstrom E.
        • Astrom-Olsson K.
        • Ohlin H.
        • Frogner F.
        • Carlsson M.
        • Billgren T.
        • Jovinge S.
        • Cain P.
        • Wagner G.S.
        • Arheden H.
        Peak CKMB and cTnT accurately estimates myocardial infarct size after reperfusion.
        Scand Cardiovasc J. 2007; 41: 44-50
        • Giannitsis E.
        • Steen H.
        • Kurz K.
        • Ivandic B.
        • Simon A.C.
        • Futterer S.
        • Schild C.
        • Isfort P.
        • Jaffe A.S.
        • Katus H.A.
        Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T.
        J Am Coll Cardiol. 2008; 51: 307-314
        • Hallen J.
        • Jensen J.K.
        • Fagerland M.W.
        • Jaffe A.S.
        • Atar D.
        Cardiac troponin I for the prediction of functional recovery and left ventricular remodelling following primary percutaneous coronary intervention for ST-elevation myocardial infarction.
        Heart. 2010; 96: 1892-1897
        • Klug G.
        • Mayr A.
        • Mair J.
        • Schocke M.
        • Nocker M.
        • Trieb T.
        • Jaschke W.
        • Pachinger O.
        • Metzler B.
        Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI.
        Clin Res Cardiol. 2011; 100: 501-510
        • Gibson C.M.
        • Maehara A.
        • Lansky A.J.
        • Wohrle J.
        • Stuckey T.
        • Dave R.
        • Cox D.
        • Grines C.
        • Dudek D.
        • Steg G.
        • Parise H.
        • Wolff S.D.
        • Cristea E.
        • Stone G.W.
        Rationale and design of the INFUSE-AMI study: a 2 x 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.
        Am Heart J. 2011; 161: 478-486.e7
        • Stone G.W.
        • Maehara A.
        • Witzenbichler B.
        • Godlewski J.
        • Parise H.
        • Dambrink J.H.
        • Ochala A.
        • Carlton T.W.
        • Cristea E.
        • Wolff S.D.
        • Brener S.J.
        • Chowdhary S.
        • El-Omar M.
        • Neunteufl T.
        • Metzger D.C.
        • Karwoski T.
        • Dizon J.M.
        • Mehran R.
        • Gibson C.M.
        Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
        JAMA. 2012; 307: 1817-1826
        • van 't Hof A.W.
        • Liem A.
        • Suryapranata H.
        • Hoorntje J.C.
        • de Boer M.J.
        • Zijlstra F.
        Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.
        Circulation. 1998; 97: 2302-2306
        • Schroder R.
        • Wegscheider K.
        • Schroder K.
        • Dissmann R.
        • Meyer-Sabellek W.
        Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial.
        J Am Coll Cardiol. 1995; 26: 1657-1664
        • Yancy C.W.
        • Lopatin M.
        • Stevenson L.W.
        • De Marco T.
        • Fonarow G.C.
        Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.
        J Am Coll Cardiol. 2006; 47: 76-84
        • Fonarow G.C.
        • Stough W.G.
        • Abraham W.T.
        • Albert N.M.
        • Gheorghiade M.
        • Greenberg B.H.
        • O'Connor C.M.
        • Sun J.L.
        • Yancy C.W.
        • Young J.B.
        Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
        J Am Coll Cardiol. 2007; 50: 768-777
        • Gibson C.M.
        • Cannon C.P.
        • Murphy S.A.
        • Marble S.J.
        • Barron H.V.
        • Braunwald E.
        Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.
        Circulation. 2002; 105: 1909-1913
        • Kandzari D.E.
        • Tcheng J.E.
        • Gersh B.J.
        • Cox D.A.
        • Stuckey T.
        • Turco M.
        • Mehran R.
        • Garcia E.
        • Zimetbaum P.
        • McGlaughlin M.G.
        • Lansky A.J.
        • Costantini C.O.
        • Grines C.L.
        • Stone G.W.
        Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
        Am Heart J. 2006; 151: 1288-1295
        • Karha J.
        • Murphy S.A.
        • Kirtane A.J.
        • de Lemos J.A.
        • Aroesty J.M.
        • Cannon C.P.
        • Antman E.M.
        • Braunwald E.
        • Gibson C.M.
        Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction.
        Am J Cardiol. 2003; 92: 913-918
        • Halkin A.
        • Stone G.W.
        • Grines C.L.
        • Cox D.A.
        • Rutherford B.D.
        • Esente P.
        • Meils C.M.
        • Albertsson P.
        • Farah A.
        • Tcheng J.E.
        • Lansky A.J.
        • Mehran R.
        Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.
        J Am Coll Cardiol. 2006; 47: 951-961
        • Cohn J.N.
        • Ferrari R.
        • Sharpe N.
        Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.
        J Am Coll Cardiol. 2000; 35: 569-582
        • Engblom H.
        • Hedstrom E.
        • Heiberg E.
        • Wagner G.S.
        • Pahlm O.
        • Arheden H.
        Rapid initial reduction of hyperenhanced myocardium after reperfused first myocardial infarction suggests recovery of the peri-infarction zone: one-year follow-up by MRI.
        Circ Cardiovasc Imaging. 2009; 2: 47-55
        • Pfeffer M.A.
        • Braunwald E.
        Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
        Circulation. 1990; 81: 1161-1172
        • Solomon S.D.
        • Glynn R.J.
        • Greaves S.
        • Ajani U.
        • Rouleau J.L.
        • Menapace F.
        • Arnold J.M.
        • Hennekens C.
        • Pfeffer M.A.
        Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.
        Ann Intern Med. 2001; 134: 451-458